title: Peripheral leukocytes with HLA-DR+/CD8- phenotype are associated with prognosis in patients with lung cancer.
abstract: BACKGROUND
  We have previously reported that the most significant immunological prognostic factors in patients with lung cancer are the percentages of peripheral HLA-DR+ lymphocytes.
  
  
  METHODS
  We performed two-color flow cytometric analyses using two combinations of double-staining to identify lymphocyte phenotypes HLA-DR/CD4 and HLA-DR/CD8, and examined the correlation between the expression of these subsets and survival in 51 patients with non-small cell lung cancer.
  
  
  RESULTS
  The percentages of HLA-DR+, HLA-DR+/CD4+ (activated helper/inducer T cells) and HLA-DR+/CD8+ (activated cytotoxic/suppressor T cells) did not correlate with survival. However, survival was better when the percentage of HLA-DR+/CD8- was below normal (p = 0.0267). The 4-year survival rate in patients with high and low percentages of peripheral HLA-DR+/CD8- lymphocytes was 26.0% and 53.2%, respectively.
  
  
  CONCLUSIONS
  The subset of HLA-DR+/CD8- lymphocytes powerfully predicts the survival of patients with non-small cell lung cancer.
authors.affiliation: Department of Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, Japan 160-0023. hanakamu@tokyo-med.ac.jp
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Nakamura
authors.forename: Hisashi
authors.initials: H
authors.lastname: Saji
authors.forename: Idiris
authors.initials: I
authors.lastname: Aute
authors.forename: Norihito
authors.initials: N
authors.lastname: Kawasaki
authors.forename: Makoto
authors.initials: M
authors.lastname: Hosaka
authors.forename: Akihiko
authors.initials: A
authors.lastname: Ogata
authors.forename: Takamoto
authors.initials: T
authors.lastname: Saijo
authors.forename: Harubumi
authors.initials: H
authors.lastname: Kato
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology*; D008297:Male; D011379:Prognosis; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D006684:HLA-DR Antigens